diffuse large b-cell lymphoma Clinical Research Trials

Please select a valid location from the dropdown

Filter By

Clear all Advanced

Advanced Filters

Gender
Phase
Study Type
Sponsors
Accepts healthy volunteers
New/Updated Trials
Online Trials

Male only (1)
Any (307)

Phase 1 (83)
Phase 2 (82)
Phase 3 (30)
Phase 4 (1)
Phase 1/2 (56)
Phase 2/3 (4)
Unknown (52)

Interventional (277)
Observational (30)

National Cancer Institute (NCI) (15)
Hoffmann-La Roche (9)
Ruijin Hospital (8)
M.D. Anderson Cancer Center (6)
Memorial Sloan Kettering Cancer Center (6)
Masonic Cancer Center, University of Minnesota (5)
The Lymphoma Academic Research Organisation (5)
Celgene (4)
Fred Hutchinson Cancer Research Center (4)
Genmab (4)
Mayo Clinic (4)
University of Washington (4)
ADC Therapeutics S.A. (3)
BeiGene (3)
City of Hope Medical Center (3)
Fondazione Italiana Linfomi ONLUS (3)
Fudan University (3)
Herlev Hospital (3)
Huiqiang Huang (3)
Novartis Pharmaceuticals (3)
Nurix Therapeutics, Inc. (3)
Second Affiliated Hospital, School of Medicine, Zhejiang University (3)
Sun Yat-sen University (3)
The First Affiliated Hospital with Nanjing Medical University (3)
Austin Health (2)
Barbara Ann Karmanos Cancer Institute (2)
Epizyme, Inc. (2)
H. Lee Moffitt Cancer Center and Research Institute (2)
Henan Cancer Hospital (2)
Hospices Civils de Lyon (2)
Juno Therapeutics, a Subsidiary of Celgene (2)
Karyopharm Therapeutics Inc (2)
MEI Pharma, Inc. (2)
Merck Sharp & Dohme LLC (2)
Miltenyi Biomedicine GmbH (2)
MorphoSys AG (2)
New York Medical College (2)
Nordic Lymphoma Group (2)
Sanofi (2)
Seagen Inc. (2)
Seoul National University Bundang Hospital (2)
Shanghai Ming Ju Biotechnology Co., Ltd. (2)
Takeda (2)
UNC Lineberger Comprehensive Cancer Center (2)
University Hospital Muenster (2)
University of Chicago (2)
University of Rochester (2)
Weprom (2)
Wuhan University (2)
2seventy bio (1)
AIDS Malignancy Consortium (1)
AVM Biotechnology LLC (1)
Acerta Pharma BV (1)
Adicet Bio, Inc (1)
Affiliated Hospital to Academy of Military Medical Sciences (1)
Antengene Corporation (1)
ArQule, Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.) (1)
Arcus Biosciences, Inc. (1)
Asan Medical Center (1)
AstraZeneca (1)
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (1)
Bambino Gesù Hospital and Research Institute (1)
Baylor College of Medicine (1)
Beijing Boren Hospital (1)
Beijing InnoCare Pharma Tech Co., Ltd. (1)
Bio-Path Holdings, Inc. (1)
Biomea Fusion Inc. (1)
Bnai Zion Medical Center (1)
Boryung Pharmaceutical Co., Ltd (1)
C. Babis Andreadis (1)
Calibr, a division of Scripps Research (1)
Cambridge University Hospitals NHS Foundation Trust (1)
Catherine Bollard (1)
Cellectar Biosciences, Inc. (1)
Central Hospital, Nancy, France (1)
Centre Antoine Lacassagne (1)
Centre Hospitalier Universitaire Dijon (1)
Centre Hospitalier Universitaire, Amiens (1)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1)
Chipscreen Biosciences, Ltd. (1)
Chongqing Precision Biotech Co., Ltd (1)
Constellation Pharmaceuticals (1)
Crystal Mackall, MD (1)
Curocell Inc. (1)
Cyclacel Pharmaceuticals, Inc. (1)
Cyteir Therapeutics, Inc. (1)
CytomX Therapeutics (1)
Dana-Farber Cancer Institute (1)
David Bond, MD (1)
Deepa Jagadeesh (1)
Duke University (1)
Eli Lilly and Company (1)
Emory University (1)
Exelixis (1)
First Affiliated Hospital of Harbin Medical University (1)
First Affiliated Hospital of Zhejiang University (1)
Fox Chase Cancer Center (1)
Fred Hutchinson Cancer Center (1)
Fujian Medical University (1)
Fundacion CRIS de Investigación para Vencer el Cáncer (1)

No (300)
Yes (8)

Updated trials (106)

No (308)

I am/have/had

I am/have/hadb-cell lymphoma

I am/have/hadmeasurable disease

I am/have/hadfollicular lymphoma

I am/have/hadhodgkin's disease

I am/have/hadcancer

I am/have/haddiffuse large b-cell lymphoma refractory

I am/have/hadgilbert's syndrome

I am/have/hadcell transplantation

I am/have/hadmantle cell lymphoma

I am/have/hadneutrophil count

I am/have/hadhigh grade b-cell lymphoma

I am/have/hadchronic lymphocytic leukemia

I am/have/hadda-epoch

I am/have/hadsalvage therapy

I am/have/hadautograft

I am/have/hadindolent lymphoma

I am/have/hadmarginal zone lymphoma

I am/have/hadburkitt's lymphoma

I am/have/hadchemoimmunotherapy

I am/have/hadleukemia

added new label for I am/have/had

I am looking for

I am looking forrituximab

I am looking forvincristine

I am looking forcyclophosphamide

I am looking fordoxorubicin

I am looking forprednisone

I am looking foranthracyclines

I am looking foretoposide

I am looking forvenetoclax

I am looking forbendamustine

I am looking forlenalidomide

I am looking foralkylating agent

I am looking formonoclonal antibodies

I am looking foranti-cd20 monoclonal antibody

I am looking forcytarabine

I am looking forconjugated bilirubin

I am looking forbtk inhibitor

I am looking forgemcitabine

I am looking forbrentuximab

I am looking fordexamethasone

I am looking foravid

added new label for I am looking for

Advanced Filters

Found 308 clinical trials

Featured trial

We call this “infoimagery”. It is unique to every trial and is generated based on a trials specific data eg. therapeutic area, study type, phase etc. and the centerwatch system associates the information to a matching set of related symbols and icons.

What's this?

Phase 1
For Seniors
For adults
For all genders
Hematology
Recruiting

A safety and Tolerability Study of INCB053915 in Combination With INCB050465 in Diffuse Large B-Cell Lymphoma

The purpose of this study is to evaluate the safety and tolerability of INCB053914 in combination with INCB050465 in relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL).

lymphomas

lymphoma

b-cell lymphoma

95 views
10 May, 2022
2 locations

Multi-country trial
Phase 1
Recruiting in 10s
Interventional Study
For all genders
Recruiting

A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL)

IHC-positive DLBCL. Approximately 50 participants will be enrolled in this study in five consecutive cohorts each consisting of approximately 10 participants.

0 views
05 May, 2022
18 locations

Multi-country trial
Phase 2
For adults
Recruiting in 100s
Interventional Study
For all genders
Recruiting

Biomarker Driven Intensified ChemoImmunotherapy With Early CNS Prophylaxis (Bio-CHIC)

large B-cell lymphoma (DLBCL).

large cell lymphoma

da-epoch

burkitt's lymphoma

chemoimmunotherapy

b-cell lymphoma

42 views
31 Jan, 2022
16 locations

Multi-country trial
Phase 1
For Seniors
For adults
Recruiting in 10s
Interventional Study
For all genders
Recruiting

AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Blood Cancer

This is a modular, multicentre, open-label, non-randomised, Phase I/II, dose-setting and expansion study including an intra-participants dose ramp up. AZD4573 will be administered intravenously, in novel combinations with anti-cancer agents, to participants with relapsed/refractory (r/r) haematological malignancies.

1 views
14 May, 2022
17 locations

Phase 3
For adults
Recruiting in 100s
Interventional Study
For all genders
Recruiting

Thalidomide Maintenance Treatment in DLBCL

This is a randomized, multi-center,phase III study to evaluate the ability of thalidomide maintenance therapy to prolong relapse-free survival in diffuse large B cell lymphoma(DLBCL).

rituximab

b-cell lymphoma

16 views
21 Jan, 2021
1 location

Phase 2
For adults
Recruiting in 10s
Interventional Study
For all genders
Recruiting

GVD±R Regimen for ASCT-eligible Patients With Refractory/Relapsed DLBCL

rituximab) regimen for autologous hematopoietic stem cell transplantation(ASCT)-eligible patients with refractory/relapsed diffuse large B-cell lymphoma.

rituximab

gemcitabine

doxorubicin

cell transplantation

b-cell lymphoma

13 views
15 Feb, 2022
1 location

Phase 2
For Seniors
For adults
Recruiting in 10s
Interventional Study
For all genders
Recruiting

Chidamide + R-GemOx Regimen as Salvage Treatment for Transplant-ineligible Patients With Relapsed/Refractory DLBCL

treatment of transplant-ineligible patients with relapsed/refractory diffuse large B-cell lymphoma.

rituximab

salvage therapy

gemcitabine

cell transplantation

b-cell lymphoma

0 views
15 Feb, 2022
1 location

For Seniors
For adults
Recruiting in 100s
Interventional Study
For all genders
Recruiting

Quality of Life of Adults With Diffuse Large B-cell Lymphoma Treated With Tisagenlecleucel

The aim of this non-interventional multi-center study is to evaluate quality of life (QOL) and other patient reported outcomes (PROs) among adults with diffuse large b-cell lymphoma (DLBCL

0 views
29 Apr, 2022
1 location

Phase 2
Recruiting in 10s
Interventional Study
For all genders
Recruiting

GPL in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma

/refractory diffuse large B-cell lymphoma.

0 views
13 May, 2022
1 location

Phase 2
Recruiting in 100s
Interventional Study
For all genders
Recruiting

Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in R/R DLBCL

The purpose of this study is to investigate the safety and effectiveness of plamotamab when it is given with tafasitamab and lenalidomide in relapsed or refractory DLBCL.

0 views
11 May, 2022
1 location